Phase 4
Completed N=10
Senescent Immunity in Elders and Vaccine Responses (SILVER)
Flu Vaccine
Source: ClinicalTrials.gov NCT04077424 ↗
Enrolled (actual)
10
Serious AEs
0.0%
Results posted
Jul 2022
Primary outcomePrimary: Hemagglutinin Antigen Inhibition Assay Titers at Baseline — 20; 160; 25; 40 antibody titers
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
To study the effects of age on the immune system's response to flu vaccine and to study the connection between the immune system and physical and cognitive changes associated with aging.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Hemagglutinin Antigen Inhibition Assay Titers at Baseline |
20; 160; 25; 40; 90; 50 | — |
| PRIMARY Hemagglutinin Antigen Inhibition Assay Titers at Day 28 |
320; 120; 480; 2560; 160; 320 | — |
Eligibility Criteria
Inclusion Criteria
- Age 65 years and over
- Independent Living (including Assisted Living)
Exclusion Criteria
- Unable to understand the consent or the study.
- Allergic to any vaccine components, excluding eggs.
- History of Guillain-Barre.
- Residing in a long -term care facility such as a nursing home.
Data sourced from ClinicalTrials.gov (NCT04077424). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.